BAT
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Serious Bacterial Infection
Conditions
Serious Bacterial Infection
Trial Timeline
Dec 25, 2020 → Jan 23, 2023
NCT ID
NCT03580044About BAT
BAT is a phase 3 stage product being developed by Pfizer for Serious Bacterial Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT03580044. Target conditions include Serious Bacterial Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03580044 | Phase 3 | Terminated |
Competing Products
4 competing products in Serious Bacterial Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Saizen® A + Saizen® B | Merck | Phase 3 | 77 |
| voriconazole IV | Pfizer | Pre-clinical | 22 |
| voriconazole tablet | Pfizer | Pre-clinical | 22 |
| TD-1607 + Placebo | Theravance Biopharma | Phase 1 | 28 |